Thermo Fisher Scientific and Samsung announce diagnostic collaboration

Thermo Fisher Scientific has announced that it will be collaborating with Samsung Electronics to jointly design, develop and market new point-of-care solutions for key applications.

The companies will work together to develop new solutions for the detection of sepsis, drugs of abuse and therapeutic drug monitoring, as well as for diagnosing cardiac problems and women's health conditions.

By signing this agreement, the partners will jointly benefit from Samsung's full suite of innovative point-of-care platforms, as well as Thermo Fisher Scientific's strong commercial sales and service channels.

Point-of-care testing enables patient diagnoses in a variety of locations, including a physician's office, inside an ambulance or anywhere in the field. This facilitates more rapid diagnosis and treatment.

Dr Marc Tremblay, president of Thermo Fisher's clinical diagnostics business, said: "We look forward to working with Samsung to add some of our leading biomarkers and assays to their platforms to create a truly differentiated testing menu."

This comes after the firm recently agreed to work with GlaxoSmithKline and Pfizer to develop a universal next-generation sequencing oncology test for solid tumours.